Parasitic Infections in HIV-Infected Patients

  • Authors: José M. Miró, MD, PhD; Miriam J. Álvarez-Martínez, MD, PhD (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/20/21 (What's New)

Summary

  • Secondary prophylaxis or chronic maintenance therapy in patients with HIV and latent Chagas disease may not be needed, particularly if ART is used[CDC OI; GESIDA OI]
  • Some clinicians suggest maintaining the same daily dose used with primary prophylaxis given 3 times per week
  • Prophylaxis should be stopped in patients receiving ART with CD4+ cell counts > 200 cells/mm3 and undetectable HIV-1 RNA

Action required

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.